Microbiome · Immunology · Cancer Immunotherapy · Hematopoietic Cell Transplantation
Credit: Antoine Doré
While cancer immunotherapy holds tremendous promise, durable responses in most disease types are achieved only in a minority of patients. For example, allogeneic hematopoietic-cell transplantation (allo-HCT) is a curative treatment for hematological malignancies, but its success is limited by relapse, graft-vs-host disease (GVHD), or infection. We and others have established that GVHD severity and mortality risk after transplantation are in part dependent on the composition of the intestinal microbiota, yet the mechanisms by which this is mediated remain poorly understood.
The Peled laboratory seeks to use human specimens and mouse models to understand how the gut microbiome and host immunity regulate one another and how these relationships might be manipulated to improve immunotherapy for patients with cancer.